Founder and CEO, Kesembe, Inc.
Noam Ziv is the former Qualcomm Corporate Research and Development Software Group Vice President of Engineering, where, for over 12 years he led teams working on low power radio design, network overlay technologies, and application of Qualcomm technologies in novel ways and to new markets. He served as an expert advisor to the XPRIZE Foundation on the $10 Million Qualcomm Tricorder XPRIZE, and as a judge in two Nokia Sensing XCHALLANGES. Noam is a regular guest faculty member for NIH mHealth training seminars.
Noam is sought out for his systems architecture and telecommunications technology expertise, designing for maximum network effect, and the application of current and upcoming technology and technology trends towards viable business models.
Noam is currently Founder and CEO of Kesembe, Inc., an Internet of Medical Things (IOMT) consulting company based in San Diego, CA, and the CTO of LuminX, an IOMT company focused on improving patient outcomes. From 2013 to 2016, Mr. Ziv was the system and software architect for BioRibbon Health, a startup that developed a unique multi sensor smart patch system. From July 2010 to January 2012, as Senior Director for Business Development at Qualcomm’s Health and Life Sciences group, Noam conceived and architected the 2net platform, a scalable IOMT solution, which became the core offering of Qualcomm Life. At Qualcomm, he evaluated and advised hundreds of medical device and health companies on technology, systems architecture, innovation, and business models.
Noam Ziv joined Qualcomm in 1989 as an engineer and worked on software architecture, design and implementations, communication protocols, algorithms, Application Specific Integrated Circuit (ASIC) and hardware designs. From 1996 to 1999 Mr. Ziv was the Project Engineer for Qualcomm’s Cellular Infrastructure project leading it to global commercial deployments.
Noam Ziv has a BS in Computer Engineering from the Technion (Israel Institute of Technology), and has been granted 24 patents.
This panel will explore the challenges and opportunities associated with patients that fail to comply with prescribed therapy and the associated issues with changing their behaviors to prevent chronic disease progression/recurrence.